MedPath

Effect of naltrexone in chronic urticaria

Not Applicable
Conditions
rticaria.
Urticaria
Registration Number
IRCT20210407050878N1
Lead Sponsor
Iran University of Medical Sciences
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Pending
Sex
All
Target Recruitment
62
Inclusion Criteria

Diagnosis of chronic urticaria based on clinical criteria
Lack of response to standard treatment
Patients of both males and females
Age over 12 years

Exclusion Criteria

Pregnancy
Breast feeding
Allergy to naltrexone
Substance abuse

Study & Design

Study Type
interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Itching Score based on UAS7 (Urticaria Activity Score7). Timepoint: Itching score based on UAS7 (Urticaria Activity Score7): During the week before beginning intervention, during the second week of intervention, during the fourth week of intervention. Method of measurement: Based on UAS7 (Urticaria Activity Score7).;Urticaria Score based on UAS7 (Urticaria Activity Score7). Timepoint: Urticaria score based on UAS7 (Urticaria Activity Score7): during the week before beginning intervention, during the second week of intervention, during the fourth week of intervention. Method of measurement: Based on UAS7 (Urticaria Activity Score7).
Secondary Outcome Measures
NameTimeMethod
Itching score based on VAS (Visual Analogue Scale). Timepoint: Before intervention, end of the second week of intervention, end of the fourth week of intervention. Method of measurement: Based on VAS (Visual Analogue Scale).;Quality of life based on DLQI (Dermatologic Life Quality Index). Timepoint: Before intervention, end of the second week of intervention, end of the fourth week of intervention. Method of measurement: Based on DLQI (Dermatologic Life Quality Index).
© Copyright 2025. All Rights Reserved by MedPath